Drug General Information
Drug ID	D0ZD3C
Former ID	DIB016028
Drug Name	Gemigliptin
Drug Type	Small molecular drug
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Phase 3	[524534]
Company	LG Life Sciences Ltd
Structure		Download 2D MOL 3D MOL
Formula	C18H19F8N5O2
Canonical SMILES	C1CN(Cc2c1c(nc(n2)C(F)(F)F)C(F)(F)F)C(=O)C[C@@H](CN1C(=<br />O)CCC(C1)(F)F)N
PubChem Compound ID	11953153
Target and Pathway
Target(s)	Dipeptidyl peptidase IV	Target Info	Inhibitor	[533009]
KEGG Pathway	Protein digestion and absorption
NetPath Pathway	IL2 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
References
Ref 524534	ClinicalTrials.gov (NCT01990469) Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin. U.S. National Institutes of Health.
Ref 533009	Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.